Abnormal uterine bleeding

Reading File
Finding Sources
Finding Sources
Searching PubMed

"abnormal uterine bleeding" AND management

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

abnormal uterine bleeding PALM-COEIN classification diagram

This diagnostic image is an intraoperative hysteroscopic photograph of the uterine cavity. The visual focus is a well-defined, oval-shaped pedunculated endometrial polyp protruding from the posterior uterine wall. The polyp demonstrates a smooth, glistening surface with a pale pink to white color, interspersed with focal areas of erythema and fine vertical striations across its body. Its morphology is slightly lobulated, and it is attached to the uterine wall by a distinct stalk. The surrounding endometrial tissue appears healthy, smooth, and pink, although there is a slight darkening near the base of the pedicle, likely representing minor blood accumulation. This clinical photograph illustrates a common structural cause of abnormal uterine bleeding (AUB), frequently categorized under the 'Polyp' component of the FIGO PALM-COEIN classification system. Such findings are critical in the diagnostic workup of perimenopausal and postmenopausal women to differentiate benign focal abnormalities from endometrial hyperplasia or malignancy.

This diagnostic image is an intraoperative hysteroscopic photograph of the uterine cavity. The visual focus is a well-defined, oval-shaped pedunculated endometrial polyp protruding from the posterior uterine wall. The polyp demonstrates a smooth, glistening surface with a pale pink to white color, interspersed with focal areas of erythema and fine vertical striations across its body. Its morphology is slightly lobulated, and it is attached to the uterine wall by a distinct stalk. The surrounding endometrial tissue appears healthy, smooth, and pink, although there is a slight darkening near the base of the pedicle, likely representing minor blood accumulation. This clinical photograph illustrates a common structural cause of abnormal uterine bleeding (AUB), frequently categorized under the 'Polyp' component of the FIGO PALM-COEIN classification system. Such findings are critical in the diagnostic workup of perimenopausal and postmenopausal women to differentiate benign focal abnormalities from endometrial hyperplasia or malignancy.

A complex pathophysiology diagram illustrating various cellular signaling pathways in the human endometrium, specifically highlighting mechanisms dysregulated in uterine fibroids. The flow begins with extracellular ligands binding to transmembrane receptors and concludes with functional physiological outcomes. Key pathways include: (1) TGF-β/SMAD signaling leading to endometrial remodeling and coagulation; (2) PGF2α/FP and ET-1/ETAR/ETBR signaling involving PLC, IP3, Calmodulin, and PKC cascades, which result in spiral artery vasoconstriction and myometrial constriction; (3) ETBR/VEGFR/PDGFR cross-talk through PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways, driving vasodilation (via NO), proliferation, and angiogenesis; and (4) TNFα/TNFR signaling through Caspase cascades (apoptosis) and JNK/AP-1 pathways. Icons with upward arrows next to ligands like TGF-β, PGF2α, and VEGF indicate molecular upregulation typically seen in the presence of uterine fibroids. This educational diagram is targeted at an advanced level, illustrating how ligand-receptor interactions contribute to heavy menstrual bleeding and abnormal uterine vascular architecture.

A complex pathophysiology diagram illustrating various cellular signaling pathways in the human endometrium, specifically highlighting mechanisms dysregulated in uterine fibroids. The flow begins with extracellular ligands binding to transmembrane receptors and concludes with functional physiological outcomes. Key pathways include: (1) TGF-β/SMAD signaling leading to endometrial remodeling and coagulation; (2) PGF2α/FP and ET-1/ETAR/ETBR signaling involving PLC, IP3, Calmodulin, and PKC cascades, which result in spiral artery vasoconstriction and myometrial constriction; (3) ETBR/VEGFR/PDGFR cross-talk through PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways, driving vasodilation (via NO), proliferation, and angiogenesis; and (4) TNFα/TNFR signaling through Caspase cascades (apoptosis) and JNK/AP-1 pathways. Icons with upward arrows next to ligands like TGF-β, PGF2α, and VEGF indicate molecular upregulation typically seen in the presence of uterine fibroids. This educational diagram is targeted at an advanced level, illustrating how ligand-receptor interactions contribute to heavy menstrual bleeding and abnormal uterine vascular architecture.

An educational comparison diagram illustrating the differences between normal and abnormal endometrium (specifically endometriosis). The top section displays two anatomical illustrations of a mammal uterus. The 'Normal endometrium' shows a smooth, uniform uterine cavity with an open, Y-shaped internal structure. The 'Abnormal endometrium diagram' depicts a constricted, triangular uterine cavity with thickened, irregular linings and growths, suggestive of ectopic tissue implantation. The bottom section presents five high-magnification grayscale diagnostic images representing cellular pathology. The normal side shows 'Early secretory cells' and 'Early basement membrane' with visible, organized textures and clear cellular arrangements. In contrast, the abnormal side shows 'Abnormal early secretory cells,' 'Abnormal early epithelial cells,' and 'Abnormal early basement membrane,' which exhibit significantly darker, less defined clusters and disrupted structural integrity. This diagram serves as a visual guide to the gross anatomical and microscopic cellular changes associated with endometrial pathology.

An educational comparison diagram illustrating the differences between normal and abnormal endometrium (specifically endometriosis). The top section displays two anatomical illustrations of a mammal uterus. The 'Normal endometrium' shows a smooth, uniform uterine cavity with an open, Y-shaped internal structure. The 'Abnormal endometrium diagram' depicts a constricted, triangular uterine cavity with thickened, irregular linings and growths, suggestive of ectopic tissue implantation. The bottom section presents five high-magnification grayscale diagnostic images representing cellular pathology. The normal side shows 'Early secretory cells' and 'Early basement membrane' with visible, organized textures and clear cellular arrangements. In contrast, the abnormal side shows 'Abnormal early secretory cells,' 'Abnormal early epithelial cells,' and 'Abnormal early basement membrane,' which exhibit significantly darker, less defined clusters and disrupted structural integrity. This diagram serves as a visual guide to the gross anatomical and microscopic cellular changes associated with endometrial pathology.

I now have sufficient information for a comprehensive response. Let me compile everything.

Abnormal Uterine Bleeding (AUB)

Definition

AUB is any change in the frequency, regularity, duration, or volume of uterine bleeding that falls outside normal parameters. Normal menstruation occurs every 24-38 days, lasts 4-8 days, with flow < 80 mL per cycle. The term "dysfunctional uterine bleeding" is now obsolete and should not be used.
Key descriptive terms:
  • Heavy menstrual bleeding (HMB): excessive flow during regular cycles
  • Intermenstrual bleeding (IMB): bleeding between cycles
  • Postcoital bleeding (PCB): bleeding after intercourse
  • Postmenopausal bleeding (PMB): any bleeding >12 months after last menstrual period

PALM-COEIN Classification (FIGO 2011)

The FIGO Working Group on Menstrual Disorders established this system to standardize AUB terminology and replace older non-specific labels.

PALM - Structural Causes

(diagnosed with imaging or histology)
CauseNotes
P - Polyp (AUB-P)Endometrial/endocervical polyps; may be sessile or pedunculated; up to 5% malignant transformation risk
A - Adenomyosis (AUB-A)Endometrial glands/stroma within the myometrium; diagnosed on ultrasound or MRI
L - Leiomyoma (AUB-L)Most common benign gynecologic tumor; affects up to 70% of women by age 50; Black patients disproportionately affected; classified by FIGO as types 0-8 based on location
M - Malignancy/Hyperplasia (AUB-M)Endometrial carcinoma and hyperplasia; must be excluded, especially in postmenopausal women

COEIN - Non-Structural Causes

CauseNotes
C - Coagulopathy (AUB-C)Up to 20% of women with HMB have an underlying coagulopathy; von Willebrand disease is most common (up to 13% of AUB cases), often first presenting at menarche
O - Ovulatory dysfunction (AUB-O)Most common non-structural cause; due to PCOS, hyperprolactinemia, thyroid disease, hypothalamic dysfunction (anorexia nervosa), perimenopause, or physiologic immaturity in adolescents
E - Endometrial (AUB-E)Primary endometrial disorders - endometritis, impaired local hemostatic mechanisms
I - Iatrogenic (AUB-I)Exogenous hormones, IUCDs, anticoagulants, tamoxifen (induces uterine abnormalities in 10-40% of users), gonadal steroids
N - Not yet classified (AUB-N)No identifiable cause found
Hysteroscopic view of endometrial polyp (AUB-P):
Endometrial polyp on hysteroscopy

Age-Based Differential Diagnosis

Age GroupLikely Causes
PrepubertalInfection, trauma/sexual abuse, vaginal foreign body, structural lesion
AdolescentsCoagulopathy (von Willebrand disease presenting at menarche), HPO axis immaturity, PCOS
Reproductive ageStructural lesions (polyps, leiomyomas), anovulation (PCOS), endometrial hyperplasia
Perimenopause (>40 years)Anovulatory bleeding, leiomyoma, endometrial hyperplasia/carcinoma
PostmenopausalAtrophy (most common), endometrial carcinoma (must be excluded), polyps

Workup and Investigations

Essential Initial Workup

  1. Pregnancy test - mandatory in all reproductive-age women
  2. Full blood count - assess for anemia; hemoglobin/hematocrit if hemodynamically unstable
  3. TSH - thyroid dysfunction (especially hypothyroidism) associated with AUB
  4. Prolactin - if anovulatory dysfunction suspected
  5. Coagulation screen (PT, aPTT, platelet count) - if bleeding since menarche, family history of coagulopathy, or signs of systemic bleeding
  6. STI screening - Chlamydia linked to AUB via endometrial inflammation
  7. Cervical cancer screening - if not up to date

Imaging

  • Transvaginal ultrasound (TVUS): first-line imaging; identifies fibroids, endometrial thickening, focal masses, adenomyosis features
    • In postmenopausal women, endometrial thickness < 4-5 mm reliably excludes endometrial cancer
  • Saline infusion sonography / 3D ultrasound: improves detection of intracavitary lesions
  • MRI: superior for fibroids (FIGO typing) and adenomyosis

Endometrial Biopsy - Indications

  • Age ≥45 years with any AUB, including IMB
  • Age < 45 with: obesity/unopposed estrogen exposure, PCOS, persistent AUB refractory to medical treatment, elevated familial cancer risk
  • Suspected endometrial pathology at any age
  • Hysteroscopy + biopsy has superior sensitivity and specificity vs. blind biopsy alone

Management

Acute/Emergency Management (heavy/unstable bleeding)

  1. Resuscitation: IV fluids, blood products for hemodynamic instability
  2. IV conjugated estrogen: 25 mg IV every 4-6 hours for up to 24 hours
  3. Intrauterine tamponade: 26Fr Foley catheter with 30 mL saline
  4. Surgical options: urgent dilation and curettage (D&C), uterine artery embolization (UAE), endometrial ablation, or hysterectomy

Medical Management (non-emergent)

AgentIndication
Combined oral contraceptive pillsOvulatory dysfunction, cycle regulation, HMB reduction
Levonorgestrel-releasing IUD (LNG-IUD)HMB, endometrial protection; first-line medical option
ProgestogensAnovulatory AUB; cyclic or continuous regimens
Tranexamic acidHMB; antifibrinolytic, used during menses only
NSAIDsHMB; reduce prostaglandin-mediated bleeding
GnRH agonistsLeiomyoma; induces amenorrhea; short-term use (bone loss)

Surgical/Procedural Management

ProcedureIndication
Hysteroscopic polypectomyUterine/endocervical polyps
MyomectomyLeiomyoma (fertility-sparing)
UAELeiomyoma, significant bleeding
Endometrial ablationHMB with completed childbearing; contraindicated if future fertility desired
HysterectomyDefinitive treatment for adenomyosis, large fibroids, refractory AUB, endometrial carcinoma

Postmenopausal Bleeding - Special Note

Postmenopausal bleeding is not included in the PALM-COEIN system - it is its own entity. Any bleeding >12 months after last period requires thorough evaluation. The most common cause is atrophy (endometrial/vaginal thinning from estrogen deficiency), but endometrial carcinoma must always be excluded. Risk factors for endometrial cancer include: obesity, diabetes, metabolic syndrome, nulliparity, age >55 years, and unopposed estrogen exposure.

Tamoxifen - Special Consideration

Women on tamoxifen for breast cancer have a 10-40% risk of uterine abnormalities (polyps, hyperplasia, endometrial cancer, rarely uterine sarcoma). Risk is time-dependent (quadruples after 5 years) but dose-independent. The standard approach is to investigate those who develop AUB rather than universal screening. Aromatase inhibitors (anastrozole, letrozole, exemestane) carry less endometrial risk as they act via a different mechanism.

Recent Evidence

A 2025 systematic review (PMID 39617186) of heavy menstrual bleeding etiology found significant rates of underlying bleeding disorders across adolescent and adult patients, reinforcing the importance of coagulopathy screening. A 2024 meta-analysis (PMID 39164326) found UAE and myomectomy broadly comparable for fibroid-related AUB, though myomectomy was favored when fertility preservation is a goal. A 2026 meta-analysis (PMID 41791665) found that anticoagulation for VTE carries substantial rates of AUB, a consideration when initiating such therapy in women.

Sources: Rosen's Emergency Medicine (Box 86.2, p. 1419-1421); Sabiston Textbook of Surgery (p. 2794-2795); Bailey and Love's Short Practice of Surgery 28th Ed. (p. 1605-1606); Robbins & Kumar Basic Pathology; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.